Literature DB >> 11751138

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.

Dianne B Hoellman1, Linda M Kelly, Kim Credito, Lauren Anthony, Lois M Ednie, Michael R Jacobs, Peter C Appelbaum.   

Abstract

Ertapenem, imipenem, meropenem, ceftriaxone, piperacillin, piperacillin-tazobactam, clindamycin, and metronidazole were agar dilution MIC tested against 431 anaerobes. Imipenem, meropenem, and ertapenem were the most active beta-lactams (MICs at which 50% of the strains are inhibited [MIC(50)s], 0.125 to 0.25 microg/ml; MIC(90)s, 1.0 to 2.0 microg/ml). Time-kill studies revealed that ertapenem at two times the MIC was bactericidal for 9 of 10 strains after 48 h. The kinetics for other beta-lactams were similar to those of ertapenem.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11751138      PMCID： PMC126985          DOI： 10.1128/AAC.46.1.220-224.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

2.  In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria.

Authors:  H M Wexler; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Authors:  E J Goldstein; D M Citron; C Vreni Merriam; Y Warren; K L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors:  J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

6.  Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.

Authors:  M R Jacobs; S K Spangler; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

7.  In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.

Authors:  I Odenholt; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

8.  Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

9.  In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

Authors:  C J Gill; J J Jackson; L S Gerckens; B A Pelak; R K Thompson; J G Sundelof; H Kropp; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 10.  Mechanisms of beta-lactam resistance in anaerobic bacteria.

Authors:  C E Nord
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec
  10 in total
  9 in total

1.  Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Authors:  Kim L Credito; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.

Authors:  Eija Könönen; Anne Bryk; Päivi Niemi; Arja Kanervo-Nordström
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

3.  Clinical and microbiological characteristics of Eggerthella lenta bacteremia.

Authors:  B J Gardiner; A Y Tai; D Kotsanas; M J Francis; S A Roberts; S A Ballard; R K Junckerstorff; T M Korman
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

Review 4.  Ertapenem: a review of its use in the treatment of bacterial infections.

Authors:  Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.

Authors:  P Cottagnoud; M Pfister; M Cottagnoud; F Acosta; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 7.  Meropenem: a review of its use in the treatment of serious bacterial infections.

Authors:  Claudine M Baldwin; Katherine A Lyseng-Williamson; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Ertapenem: a review of its use in the management of bacterial infections.

Authors:  Monique Curran; Dene Simpson; Caroline Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

Authors:  Kim L Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.